v3.26.1
Acquisitions, Dispositions, and Funded Research and Development Arrangements - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Apr. 20, 2026
Jul. 31, 2026
Jul. 25, 2025
Jul. 26, 2024
Apr. 24, 2026
Jul. 16, 2026
Jun. 12, 2026
Apr. 19, 2026
Business Combination [Line Items]                
Goodwill   $ 43,187     $ 42,587      
Fair value of contingent consideration   275     163      
Revenue   12 $ 36          
Other operating expense (income), net   123 $ 70          
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                
Business Combination [Line Items]                
Additional funding   237            
Milestone payments         1,200      
Other operating expense (income), net         157      
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesCurrent                
Business Combination [Line Items]                
Fair value of contingent consideration   111     32      
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesNoncurrent                
Business Combination [Line Items]                
Fair value of contingent consideration   $ 164     131      
CathWorks Ltd                
Business Combination [Line Items]                
Ownership percentage               15.00%
Gain on investments         $ 45      
Scientia Vascular (Scientia)                
Business Combination [Line Items]                
Goodwill             $ 511  
Other intangible assets             278  
Fair value of contingent consideration             123  
Scientia Vascular (Scientia) | IPR&D                
Business Combination [Line Items]                
Business combination, recognized asset acquired, identifiable intangible asset, indefinite-lived             13  
Scientia Vascular (Scientia) | Purchased technology and patents                
Business Combination [Line Items]                
Other intangible assets             109  
Scientia Vascular (Scientia) | Purchased technology and patents | Minimum                
Business Combination [Line Items]                
Estimated useful life       6 years        
Scientia Vascular (Scientia) | Purchased technology and patents | Maximum                
Business Combination [Line Items]                
Estimated useful life       9 years        
Scientia Vascular (Scientia) | Customer-related                
Business Combination [Line Items]                
Other intangible assets             $ 155  
Estimated useful life       18 years        
SPR Therapeutics, Inc                
Business Combination [Line Items]                
Goodwill           $ 422    
Other intangible assets           241    
Fair value of contingent consideration           0    
SPR Therapeutics, Inc | Purchased technology and patents                
Business Combination [Line Items]                
Other intangible assets           225    
Estimated useful life       15 years        
SPR Therapeutics, Inc | Customer-related                
Business Combination [Line Items]                
Other intangible assets           $ 15    
Estimated useful life       4 years        
CathWorks Ltd                
Business Combination [Line Items]                
Goodwill $ 555              
Other intangible assets 200              
Fair value of contingent consideration $ 115              
Business combination, voting equity interest acquired, percentage 85.00%              
CathWorks Ltd | Purchased technology and patents                
Business Combination [Line Items]                
Estimated useful life 10 years